ClinicalTrials.Veeva

Menu

Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma

N

National Cancer Center (NCC)

Status and phase

Unknown
Phase 2

Conditions

Stomach Neoplasms

Treatments

Drug: S-1,oxaliplatin

Study type

Interventional

Funder types

Other

Identifiers

NCT00515190
82-31-920-1609
NCCCTS-07-265

Details and patient eligibility

About

Randomized phase II study designed to evaluate the efficacy and safety of continuous S-1 plus oxaliplatin versus intermittent S-1 plus oxaliplatin as first-line therapy in patients with recurrent and/or metastastic gastric carcinoma. Within 2 weeks of the end of induction chemotherapy of 6 cycles with S-1 plus oxalipatin, patients who don't experience progression will be randomized to the continuous S-1 plus oxaliplatin arm or the intermittent S-1 plus oxaliplatin arm in a 1:1 ratio.

Enrollment

198 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Histologically or cytologically confirmed gastric adenocarcinoma with recurrent and/or metastatic disease
  2. Age ≥ 18 years
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  4. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) or non-measurable evaluable
  5. No prior treatment for recurrent and/or metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study; prior oxaliplatin is not allowed)
  6. Adequate major organ function including the following: Hematopoietic function: ANC >= 1,500/mm3, Platelet >= 100,000/mm3, Hepatic function: serum bilirubin =< 1.5 x ULN, AST/ALT levels =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)Renal function: serum creatinine =< 1.5 x ULN
  7. Patients should sign a written informed consent before study entry

Exclusion criteria

  1. Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not those with a jejunostomy probe), or inability to take oral medication

  2. Patients with active (significant or uncontrolled) gastrointestinal bleeding

  3. Residual relevant toxicity resulting from previous therapy (with the exception of alopecia) ≥ grade 2 NCI-CTCAE version 3.0

  4. Prior and/or current history of peripheral neuropathy

    • grade 1 NCI-CTCAE version 3.0
  5. Inadequate cardiovascular function:New York Heart Association class III or IV heart diseaseUnstable angina or myocardial infarction within the past 6 monthsHistory of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality

  6. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy

  7. Other malignancy within the past 3 years except non-melanomatous skin cancer or carcinoma in situ of the cervix

  8. History of or current brain metastases

  9. Psychiatric disorder that would preclude compliance

  10. Females with a positive or no pregnancy test (within 7 days before treatment start) until childbearing potential can be otherwise excluded (postmenopausal i.e. amenorrheic for at least 2 years, hysterectomy or oophorectomy)

  11. Subjects with reproductive potential not willing to use an effective method of contraception

  12. Lactating women

  13. Known dihydropyrimidine dehydrogenase deficiency

  14. Patients receiving a concomitant treatment with drugs interacting with S-1 such as flucytosine, phenytoin, or warfarin et al.

  15. Major surgery within 4 weeks of start of study treatment, without complete recovery

  16. Radiotherapy within 4 weeks of start of study treatment; 2 weeks interval allowed if palliative radiotherapy was given to bone metastatic site and patient recovered from any acute toxicity

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

198 participants in 2 patient groups

A
Active Comparator group
Description:
(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
Treatment:
Drug: S-1,oxaliplatin
B
Active Comparator group
Description:
(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
Treatment:
Drug: S-1,oxaliplatin

Trial contacts and locations

1

Loading...

Central trial contact

Se Youn Jang, M.S.; Sook Ryun Park, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems